Sodium/Iodide Symporter (NIS). The epitope is thought to be in the region of amino acids 625-643 of human NIS. The antibody may show some reactivity to Maltose Binding Protein.
Immunogen
Epitope: a.a. 625-643
Maltose Binding Protein fusion protein corresponding to amino acids 468-643 of human NIS (C-terminus).
Application
Detect Sodium/Iodine Symporter using this Anti-Sodium/Iodine Symporter Antibody, a.a. 625-643, clone FP5A validated for use in IH, IH(P) & WB.
Immunoblotting. The antibody recognizes a major band at ~97 kDa and minor bands at 15 kDa, 30 kDa, 68 kDa and 160 kDa.
Immunohistochemistry. The antibody works on paraffin embedded tissue sections which have been subjected to antigen retrieval with 10 mM citrate buffer steam for 30 minutes.
Optimal working dilutions must be determined by end user.
Physical form
Format: Purified
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Not finding the right product?
Try our Product Selector Tool.
Storage Class
10 - Combustible liquids
wgk_germany
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Journal for immunotherapy of cancer, 11(4) (2023-04-06)
Gastric cancer (GC) that metastasizes to the peritoneum is fatal. CF33 and its genetically modified derivatives show cancer selectivity and oncolytic potency against various solid tumors. CF33-hNIS and CF33-hNIS-antiPDL1 have entered phase I trials for intratumoral and intravenous treatments of
Clinical cancer research : an official journal of the American Association for Cancer Research, 25(19), 5997-6008 (2019-06-15)
The innate tumor homing potential of mesenchymal stem cells (MSCs) has been used for a targeted delivery of the theranostic sodium iodide symporter (NIS) transgene into solid tumors. We have previously shown that external beam radiotherapy (EBRT) results in the
New treatment strategies are urgently needed for glioblastoma (GBM)-a tumor resistant to standard-of-care treatment with a high risk of recurrence and extremely poor prognosis. Based on their intrinsic tumor tropism, adoptively applied mesenchymal stem cells (MSCs) can be harnessed to
JAMA otolaryngology-- head & neck surgery, 141(8), 739-744 (2015-06-05)
Sodium iodide symporter (NIS) expression in adenoid cystic carcinoma (ACC) has not been fully elucidated in the literature, and it is unclear whether radioactive iodine may be a potential therapeutic modality. To our knowledge, the present study includes the largest
Sodium iodide symporter (NIS) gene transfer for active accumulation of iodide in tumor cells is a powerful theranostic strategy facilitating both diagnostic and therapeutic application of radioiodide. In glioblastoma (GBM), the blood-brain barrier (BBB) presents an additional delivery barrier for
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.